D1064
Dihydrokainic acid
≥98% (HPLC), GLT-1 glutamate transporter inhibitor, powder
동의어(들):
2-Carboxy-4-isopropyl-3-pyrrolidineacetic acid
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C10H17NO4
CAS 번호:
Molecular Weight:
215.25
UNSPSC Code:
12352106
PubChem Substance ID:
NACRES:
NA.77
MDL number:
제품 이름
Dihydrokainic acid, ≥98% (HPLC), powder
Quality Level
assay
≥98% (HPLC)
form
powder
solubility
H2O: >10 mg/mL
storage temp.
2-8°C
SMILES string
CC(C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O
InChI
1S/C10H17NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h5-7,9,11H,3-4H2,1-2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s1
InChI key
JQPDCKOQOOQUSC-OOZYFLPDSA-N
Gene Information
human ... SLC1A1(6505), SLC1A2(6506), SLC1A3(6507)
rat ... Slc1a2(29482), Slc1a3(29483)
관련 카테고리
Application
Dihydrokainic acid has been used as a glutamate transporter (GLT-1) inhibitor in the glutamate uptake assay of astrocytes and glial cells. It may be used as a GLT-1 inhibitor in Lateral habenula (LHb).
Biochem/physiol Actions
Dihydrokainic acid is a selective GLT-1 glutamate transporter inhibitor; weak inhibitor of AMPA/kainate glutamic acid receptors at high concentrations.
Dihydrokainic acid is a selective inhibitor of the GLT-1 glutamate transporter. At higher concentrations, dihydrokainate is a weak inhibitor of AMPA/kainate glutamic acid receptors.
Dihydrokainic favors neuronal cell death. It modulates anxiety and depression behaviors.
Features and Benefits
This compound is featured on the Excitatory Amino Acid Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Rescue of glutamate transport in the lateral habenula alleviates depression-and anxiety-like behaviors in ethanol-withdrawn rats
Kang S, et al.
Neuropharmacology, 129(11), 47-56 (2018)
Anita J Bechtholt-Gompf et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35(10), 2049-2059 (2010-06-10)
Mood disorders are associated with regional brain abnormalities, including reductions in glial cell and neuron number, glutamatergic irregularities, and differential patterns of brain activation. Because astrocytes are modulators of neuronal activity and are important in trafficking the excitatory neurotransmitter glutamate
Scott M Rawls et al.
Drug and alcohol dependence, 107(2-3), 261-263 (2009-12-17)
Glutamate transporter subtype 1 (GLT-1) activation is a promising - and understudied - approach for managing aspects of morphine tolerance caused by increased glutamatergic transmission. Identification of beta-lactam antibiotics as pharmaceuticals which activate GLT-1 transporters prompted us to hypothesize that
Catherine S John et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 37(11), 2467-2475 (2012-06-29)
Major depression is associated with both dysregulated glutamatergic neurotransmission and fewer astrocytes in limbic areas including the prefrontal cortex (PFC). These deficits may be functionally related. Notably, astrocytes regulate glutamate levels by removing glutamate from the synapse via the glutamate
Meredith L Lee et al.
Journal of neurochemistry, 143(5), 489-506 (2017-08-05)
Neuron-secreted factors induce astrocytic expression of the glutamate transporter, GLT-1 (excitatory amino acid transporter 2). In addition to their elaborate anatomic relationships with neurons, astrocytes also have processes that extend to and envelop the vasculature. Although previous studies have demonstrated
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.